Idiopathic intracranial hypertension: demographic profile, clinical features, associations and clinical and visual outcomes in black African patients presenting to St John Eye Hospital by Alli, Hassan Dawood
M MED RESEARCH REPORT 
 
 
 
IDIOPATHIC INTRACRANIAL HYPERTENSION: 
DEMOGRAPHIC PROFILE, CLINICAL FEATURES, 
ASSOCIATIONS AND CLINICAL AND VISUAL 
OUTCOMES IN BLACK AFRICAN PATIENTS 
PRESENTING TO ST JOHN EYE HOSPITAL 
 
 
 
HASSAN DAWOOD ALLI 
 
DIVISION OF OPHTHALMOLOGY 
DEPARTMENT OF NEUROSCIENCES 
FACULTY OF HEALTH SCIENCES 
UNIVERSITY OF THE WITWATERSRAND 
 
2010 
ii 
IDIOPATHIC INTRACRANIAL HYPERTENSION: DEMOGRAPHIC 
PROFILE, CLINICAL FEATURES, ASSOCIATIONS AND CLINICAL 
AND VISUAL OUTCOMES IN BLACK AFRICAN PATIENTS 
PRESENTING TO ST JOHN EYE HOSPITAL 
 
 
 
 
Hassan Dawood Alli 
 
 
 
 
 
 
 
A research report submitted to the Faculty of Health Sciences, University of the  
Witwatersrand, Johannesburg, in partial fulfilment of the requirements for the degree of  
Masters of Medicine in Ophthalmology . 
 
 
Johannesburg, 2010 
 
iii 
Declaration 
 
I declare that this research report is my own unaided work. It is being submitted for the   
degree of Master of Medicine in Ophthalmology at the University of the Witwatersrand,   
Johannesburg. It has not been submitted before for any degree or examination at this or  
any other university. 
 
 
 
 
_____________________                                                     _ day of ____________ 2010 
Hassan Dawood Alli 
 
 
 
 
 
 
 
 
The work reported in this research report was carried out in the Department of  
Ophthalmology, St John Eye Hospital/Chris Hani Baragwanath Hospital, Johannesburg,  
South Africa. 
iv 
Dedication 
 
This research report is dedicated to my late mother, my family and my friends. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 Abstract 
 
Aim  
To determine and document the demographic profile, clinical features, associations and 
clinical and visual outcomes in black African patients with idiopathic intracranial 
hypertension (IIH) attending St John Eye Hospital during 2006 and 2007.  
Method 
A retrospective descriptive study was conducted on black African IIH patients. Patient files 
and data of 21 of 32 IIH patients, seen in the Neuro-ophthalmology clinic at St John Eye 
Hospital over a two year period (2006 and 2007), were available and this study is based on 
these 21 patients.  
All 21 patients fulfilled the modified Dandy criteria for the diagnosis of IIH.  
Information obtained from files of the 21 patients were recorded on a data capture sheet. 
The demographics, initial (presenting) and final visual acuities and visual fields, initial and 
final clinical symptoms and signs, associations and treatment modalities were recorded on 
the data capture sheet. Visual and clinical outcomes were determined by comparing the 
final with the initial (presenting) symptoms and signs. The minimum follow-up period 
between the initial and the final visit was two months. Patients were regarded as legally 
blind if they had severe to profound visual acuity and/or visual field loss.  
Results 
All 21 patients were female and black African. Mean age was 31.2 ± 8.9 years (range 16 – 
50 years). Mean period of follow up was 19.9 ± 20.1 months (range 2 – 77 months). 71.4% 
were obese. All patients presented with symptoms. The commonest presenting symptom 
was headache (90%) followed by visual loss (67%), transient visual obscurations (38%) 
and diplopia (29%). The results of the presenting signs were as follows: Seven eyes (17%) 
had visual acuity loss (most of which were mild [9.5%]), seven patients (33%) had 
abduction deficits, four patients (9.5%) had unilateral abnormal pupil reactions and all 
patients had papilloedema. Of the recorded associations seven patients (33%) were 
hypertensive, six (29%) were on contraception (two [9.5%] were on oral contraception) 
and two (9.5%) were taking prednisone prior to presentation. After the initial visit, all 21 
vi 
IIH patients were treated with acetazolamide (Diamox) and weight loss was recorded in 
three patients (14%). Two patients (9.5%) had optic nerve sheath fenestrations (ONSF), 
two (9.5%) had lumbar-peritoneal shunts (LPS) and six (28.6%) had multiple lumbar 
punctures (LP’s). The outcome analysis was as follows: Symptoms in 19 patients (90%) 
improved but 16 patients (76%) still had papilloedema. Two patients (9.5%) had abduction 
deficits at the final visit. Visual acuity loss occurred in five eyes (12%) at the final visit 
compared to seven eyes (17%) at the initial visit (presentation). From the initial visit 
(presentation) to the final visit, visual acuity in seven eyes (16%) improved, 31 eyes (74%) 
remained stable and four eyes (10%) worsened. Although visual fields in 33 eyes (79%) 
improved from the initial to the final visit, 36 eyes (86%) still had visual field loss at the 
final visit. 26% of eyes had severe to profound visual impairment i.e. were legally blind, at 
the final visit. 
Conclusion 
The results of 21 black African IIH patients reported in this study were similar to some 
other studies with regards to demographics, clinical features and clinical and visual 
outcomes. An association between IIH and oral contraceptives, steroids and hypertension 
could not be established. Although symptoms resolved in most patients, a significant 
number of patients still had papilloedema and visual field loss following treatment. Despite 
treatment, a quarter of the patients were legally blind at the final visit, indicating that this 
condition is not benign. 
 
 
 
 
 
 
 
 
vii 
           Presentations Arising From This Study 
 
1. Presented at the University of the Witwatersrand Neurosciences meeting on the 
5
th 
August 2009. 
2. Presented at the Ophthalmological Society of South Africa (OSSA) Congress 
on 13 February 2010. 
 
  
 
 
  
  
viii 
Acknowledgements 
 
Many thanks to: 
My supervisor and mentor, Dr Ismail Mayet, for his continual guidance, encouragement,  
advice and assistance with the study and the completion of this research report. 
 
My co-supervisor, Professor Trevor Carmichael for his advice and assistance with the 
study. 
 
My friends at St John Eye Hospital for their support. 
 
All the patients and staff at St John Eye Hospital for making the study possible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
Contents 
                                                                                                                                               
                                                                                                          Page 
Declaration                                                                                                            iii 
Dedication                                                                                                             iv     
Abstract                                                                                                                  v   
Presentations Arising From This Study                                                                vii    
Acknowledgements                                                                                              viii   
Contents                                                                                                                 ix   
List of Figures                                                                                                        x   
List of Tables                                                                                                         xi  
Nomenclature                                                                                                        xii  
Chapter 1     Introduction                                                                                      1 
Chapter 2     Methods and Materials                                                                    7               
Chapter 3     Results                                                                                              10 
Chapter 4     Discussion                                                                                                 21 
Chapter 5     Conclusion                                                                                                24 
Appendix A Data capture sheet                                                                                    25 
Appendix B Visual acuity classification and grading of all IIH patients              26 
Appendix C Visual field classification and grading of all IIH patients                27 
References                                                                                                             28           
 
 
 
 
 
 
 
 
 
 
 
x 
List of Figures 
 
Figure                                                                                                                  Page                                               
 
3.1 Age distribution of patients presenting with IIH                                              10                        
3.2 Distribution of follow-up period of IIH patients                                              11                                    
3.3 Pie chart of analysis of obesity                                                                         11                                   
3.4 Box and Whisker plot of lumbar puncture opening pressure (LPOP)              15                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                 
                                                                                                                   
 
 
xi 
List of Tables 
 
Table                                                                                                               Page                               
 
3.1   Presenting features                                                                                     12           
3.2   Clinical presentations                                                                                 13                                 
3.3   Associations                                                                                               14                                                                                                                                           
3.4   Management                                                                                               16                                      
3.5   Clinical outcomes                                                                                       17 
3.6   Analysis of initial and final visual acuities.                                               18                                                                                        
3.7   Analysis of visual acuity grading                                                               19                                             
3.8   Analysis of visual field classification and blind spot size                          20                                          
3.9   Analysis of visual field grading                                                                  20                                          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
Nomenclature 
 
APD                                                    afferent pupil defect 
BMI                                                     body mass index 
CEO                                                    Chief Executive Officer 
CF                                                       counting fingers 
C. H. Baragwanath Hospital               Chris Hani Baragwanath Hospital                    
cm H20                                                centimetre of water 
CSF                                                     cerebrospinal fluid 
CT scan                                               computer tomography scan 
HM                                                      hand movements 
 
IIH                                                      idiopathic intracranial hypertension 
 
IIHWOP                                              idiopathic intracranial hypertension without pressure 
LP                                                        lumbar puncture 
LPOP                                                   lumbar puncture opening pressure 
LPS                                                      lumbar-peritoneal shunt 
MRI                                                     magnetic resonance imaging 
NR                                                       no record 
ONSF                                                  optic nerve sheath fenestration 
OSSA                                                  Ophthalmological Society of South Africa 
RAPD                                                  relative afferent pupil defect 
SJEH                                                   St John Eye Hospital 
SOL                                                     space occupying lesion 
USA                                                    United States of America        
VA                                                       visual acuity  
VF                                                        visual field  
1 
 
CHAPTER 1 
 
1.0 INTRODUCTION   
  
1.1 Background 
 
Idiopathic Intracranial Hypertension (IIH), also known as pseudotumor cerebri and benign 
intracranial hypertension, is a condition characterized by an increase in intracranial 
pressure and no hydrocephalus or space occupying lesion (SOL) on brain imaging 
[computed tomography (CT) or magnetic resonance imaging (MRI)]; cerebrospinal fluid 
(CSF) composition is normal.
1 
Except for papilloedema (bilateral swelling of optic discs 
due to raised intracranial pressure) and abducens nerve paresis, neurologic examination is 
normal. Significant morbidity can occur because of loss of visual function and headache. 
The visual and other ophthalmological outcomes of IIH are highly variable.  
IIH is rare in hospital-based studies.
2, 3
 
IIH is strongly associated with obese, young women. It may be seen in association with 
hypertension, endocrine abnormalities, pregnancy and certain drugs and medications.
4-6
 
A Pubmed search revealed only a few published studies on IIH from Africa. These 
included studies from Libya by Radhakrishnan et al. and a case series (6 patients) from 
Kenya.
7, 8
 There are no published studies from Southern Africa, evaluating the 
demographic profile, clinical features, associations and clinical and visual outcomes in 
black patients with IIH. 
 
 
1.2 Research objective 
 
To determine and to document the demographic profile, clinical features, frequency of 
associations and clinical and visual outcomes in a study group of black African patients 
attending St. John Eye Hospital (SJEH) during the period 2006 and 2007. 
 
 
2 
 
1.3 Epidemiology 
 
The annual incidence of IIH varies according to different population-based 
epidemiological studies.
1, 7, 9
 In all these studies, the incidence is higher in young, obese 
females. 
Durcan et al. reported an annual incidence of 0.9 per 100 000 persons in the general 
population of Iowa.
1
 When obesity and gender were considered, this incidence increased to 
19.3 per 100 000 persons in overweight females between 20 and 44 years of age. The 
female to male ratio was 8:1. 
Radhakrishnan et al. reported an annual incidence of 2.2 per 100 000 persons in the general 
population of Benghazi, northeastern Libya.
7
 This incidence increased to 21.4 per 100 000 
persons in obese females between 15 and 44 years of age. 
A more recent study in
 
Israel reported an annual incidence of 0.57 to 0.9 per 100 000 
persons in the general population. This incidence increased to 4.02 per 100 000 females 
aged 15 to 45 years.
9
 
Studies based on hospital experience also indicate that IIH is rare. Between 1939 and 1975, 
Corbett et al. treated 57 IIH patients at the University of Iowa in the United States of 
America.
2
 Craig et al. reported 42 patients over a 5 year period from 1991 until 1995 at the 
Royal Victoria Hospital (RVH) in Belfast, Northern Ireland.
3
 
 
1.4 Clinical features 
 
 The most common presenting symptom in IIH is headache, either intermittent or 
permanent, usually worse in the morning and with recumbent position.
2, 5, 10
 
Monocular or binocular transient visual obscurations (TVO) may accompany the headache 
or occur independently.
1, 6 
Lasting only a few seconds, they vary from slight blurring of 
vision to light perception and they may be provoked or exacerbated by changes in posture 
from supine to upright, physical exertion or valsalva manoeuvres. 
 
Sustained visual loss can occur as a presenting feature. 26% of patient’s in Wall and 
George’s study presented with sustained visual loss.5 
3 
Intermittent or constant horizontal binocular diplopia usually indicates a sixth cranial nerve 
palsy which is the only cranial nerve palsy to occur commonly in IIH.
2, 5
  
Other presenting symptoms include tinnitus, nausea and vomiting. 
Significant morbidity associated with IIH are loss of visual function and headaches. 
Celebisoy et al. reported an abnormal visual acuity in 27% and an abnormal visual field in 
71% of patients  at the initial visit.
10
 The degree of visual field changes worsened in 22% 
of patients; in 51% it improved and in 27% it was stationary. Similar results were found in 
Wall and George’s study.5 
Although rare, IIH can potentially result in blindness. In Wall and George’s study 4% of 
patients became blind in both eyes.
5
 In the series of Corbett et al., 12% of patients became 
blind in one or both eyes.
2
 
A recent study by Bruce et al.,from Atlanta, USA, concluded that black patients were 3.5 
times more likely to develop severe visual loss than non-black patients and nearly five 
times as likely to be legally blind.
11
 They suggested that race may be an independent risk 
factor for severe visual loss. No such racial differences were found in Wall and George’s 
study.
5
 
 
 
1.5 Diagnosis  
 
There is no specific diagnostic test for IIH. Together with the clinical symptoms and signs, 
a combination of tests are used to make the diagnosis. These include neuroimaging (CT 
scan or MRI), lumbar puncture opening pressure (LPOP) and CSF composition.  
To establish a diagnosis of IIH, the following modified Dandy criteria are used: i) normal 
neuroimaging (CT or MRI) i.e. no space occupying lesion (SOL) and no ventriculomegaly, 
ii) elevation of lumbar puncture opening pressure (LPOP) > 20 cm H2O, iii) normal CSF 
composition and iv) normal neurologic examination except for papilloedema and abducens 
nerve paresis.
12 
Exceptions to the diagnostic criteria can occur. IIH without papilloedema 
(IIHWOP) has been reported.
13, 14
 Normal-pressure IIH has also been reported.
15 
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1.6 Pathogenesis  
 
The pathogenesis of IIH is poorly understood. Though many case reports and uncontrolled 
studies have reported associations between IIH and obesity, pregnancy, intracranial venous 
sinus thrombosis, certain medical conditions (anaemia, hypertension, hyperthyroidism, 
Addison’s disease etc.) and certain medications (tetracycline, nalidixic acid, indocid, 
corticosteroid, vitamin A, oral contraceptive etc.), the strongest risk factors for IIH are 
obesity and female gender, especially amongst those in the reproductive age group.
4, 6
  
Several hypotheses regarding the aetiology of IIH have been suggested, but no one 
hypothesis has been able to account for all the manifestations of the disease. 
  
Metabolic and endocrine 
Dysregulation of insulin, glucose metabolism, sex hormones, adipokines (leptin and 
ghrelin) , glucocorticosteroids, lipids and free fatty acids in obesity could predispose to 
IIH.
16
 The exact mechanism is unknown. The possible link between metabolic disorders 
and the pathogenesis of IIH is a thrombotic tendency due to dysregulation of haemostatic 
risk factors.
16
 This could result in cerebral sinus thrombosis or parasagittal venous lacunae 
thrombosis, with subsequent impaired resorption of cerebrospinal fluid and venous 
hypertension. 
 
Vitamin A toxicity 
For a long time, vitamin A excess has been implicated in the pathogenesis of IIH. The 
finding of increased levels of free retinol and decreased levels of retinol binding protein 
(RBP) supports this hypothesis.
17 
Free retinol is thought to be toxic to the arachnoid villi. 
This toxicity is postulated to decrease CSF re-absorption by the arachnoid villi leading to 
IIH. 
 
Intracranial venous hypertension 
Karahalios et al. suggested that increase in intracranial venous pressure, which leads to an 
increase in CSF and intracranial pressure by resisting CSF absorption, may be a universal 
mechanism in IIH of different aetiologies.
18 
5 
Sugarman et al. postulated that obesity leads to IIH via elevated intra-abdominal pressure, 
which impedes venous return from the brain to the heart, resulting in increased intracranial 
venous pressure and increased intracranial pressure.
19 
 
 
1.7 Management 
 
Interventions and treatments of IIH target: (1) resolving the condition, (2) preventing 
visual loss, (3) treating headaches, and (4) improving quality of life. Weight loss in obese 
patients can result in resolution of the condition.
20, 21
  Medical therapies to treat symptoms 
and to prevent visual loss are mainly diuretics aimed at lowering CSF pressure. Surgical 
therapies are used when medical therapy fails or when severe and rapid visual loss occurs 
at onset. 
 
Weight loss 
A retrospective series evaluating the effect of weight loss on visual function and 
papilloedema grade in 58 IIH patients showed more rapid improvement in papilloedema 
and visual fields in overweight women who lost weight than in those who did not lose 
weight.
22 
 
Medical management
 
Acetazolamide, which is a carbonic anhydrase inhibitor, is the most commonly used drug 
to treat IIH.
5, 23, 24
 It decreases CSF production by the choroid plexus. Doses of 0.5-1 g/day 
are generally used and can be increased until clinical improvement is achieved or a dose of 
3-4 g/day is reached. Side effects may include nausea and vomiting, peri-oral and distal 
limb paraesthesias, fatigue, depression and anorexia.
 
Topiramate, an anticonvulsant drug, is an attractive option for treating IIH.
25
 It has 
multiple mechanisms of action including inhibition of CSF production and appetite 
suppression causing weight loss. It is also effective in resolving headaches.
 
Side effects 
include acute angle-closure glaucoma, myopia and concentration difficulties. 
6 
Diuretics such as furosemide are also used to treat IIH, but are considered second-line 
treatment.
5
 It is less potent than acetazolamide and it’s mechanism of action in reducing 
increased intracranial pressure is not clear. 
Panagopoulos has reported on somatostatin analogues as a useful alternative to existing 
treatments for IIH.
26
 Further studies are needed to confirm this. 
Corticosteroids are useful in treating IIH patients with rapid visual loss while waiting for a 
surgical procedure such as an optic nerve sheath fenestration (ONSF).
27
 It is not 
recommended for routine and long-term management of IIH. 
Surgical management 
Surgical therapies are usually indicated when there is progressive loss of vision and 
persistent headache despite maximum medical therapy or when there is severe or rapid loss 
of vision at onset.
28, 29
 Surgical options include optic nerve sheath fenestration (ONSF) and 
CSF diversion procedures. There is no strong evidence to suggest that one procedure is 
superior to the other. Often the decision to use either one of these procedures depends on 
the available resources and expertise. 
Optic nerve sheath fenestration is usually  the first-line procedure when loss of vision is the 
primary problem.
29
 In one study, 88% of IIH patients had stabilization or improvement in 
visual fields after ONSF.
30
 The procedure involves creating a defect in the dural sheath of 
the optic nerve behind the eye. The exact mechanism of action is uncertain but it is thought 
that ONSF functions through CSF filtration. Although complications may occur, most are 
transient and self-limiting. Complications may include diplopia, pupillary abnormalities 
and visual loss. 
CSF diversion procedures include ventriculoperitoneal and lumbar-peritoneal shunting. 
These procedures are indicated in patients with visual loss associated with severe 
headache.
29
 Widespread use is limited by infections, the need for repeated revisions and a 
high overall failure rate. Burgett et al., in their study, showed lumbar-peritoneal shunting to 
be effective in reducing CSF pressure, relieving headaches and improving visual function 
in patients with IIH.
31 
Other surgical therapies that are rarely considered in IIH are 1) venous sinus stenting for 
patients with CSF outflow obstruction secondary to fixed venous sinus stenosis and 2) 
gastric weight reduction surgery for morbidly obese patients.
14, 32
  
7 
CHAPTER 2 
 
2.0 METHODS AND MATERIALS   
 
A retrospective, descriptive study of patients with the diagnosis of Idiopathic Intracranial 
Hypertension (IIH) was conducted at St John Eye Hospital (SJEH). 32 IIH patients 
attended the Neuro-ophthalmology clinic over a 2 year period (1 January 2006 to 31 
December 2007). Files of only 21 patients were available, and therefore the following 
analysis are of these 21 patients. Permission to review files was obtained from the Chief 
Executive Officer (CEO) of SJEH / C.H. Baragwanath Hospital. The Human Research 
Ethics Committee of the University of the Witwatersrand approved the study (Clearance 
certificate number M070907). The protocol for the study was approved by the 
Postgraduate Committee of the Department of Neurosciences, Faculty of Health Sciences, 
University of the Witwatersrand. 
All patients fulfilled the following criteria for IIH: Modified Dandy criteria 
12
  
1) Elevation of cerebrospinal fluid opening pressure (> 20 cm H2O). 
2) Normal CSF composition. 
3) Normal neuroimaging [computed tomography (CT) or magnetic resonance imaging 
(MRI)] i.e. absence of space occupying lesion (SOL) and no ventriculomegaly. 
4) Normal neurologic examination, except for papilloedema and abducens nerve 
paresis. 
The following information was obtained from patients files and captured on the data 
capture sheet (Appendix A): 
1) Demographics: Age, gender, and race. 
2) History: Symptoms (headaches, visual loss, transient visual obscurations, double 
vision, and nausea and vomiting), duration of symptoms, obesity or recent weight 
gain, pregnancy, medical conditions, and concomitant medication use. 
3) Examination: Visual acuity, ocular motility, pupil reactions, and fundus 
examination (especially the optic discs) of both eyes at the initial and last/final 
visit. 
8 
4) Investigations: Neuroimaging (CT scan or MRI), lumbar puncture (CSF opening 
pressure and CSF composition), visual fields of both eyes (initial and last/final 
visit). 
5) Management: Weight loss, medical treatment (acetazolamide, steroids), and 
surgical therapies (optic nerve sheath fenestration [ONSF], lumbar-peritoneal shunt 
[LPS] and multiple lumbar punctures [LP’s]). 
These data were entered into a Microsoft Excel spreadsheet. 
The mean age of presentation, mean follow-up period (period between initial visit 
[presentation] and last/final visit) and mean lumbar puncture opening pressure (LPOP) 
were determined.  
Percentages were calculated for the following parameters:  
(1) Obesity which was assessed according to personal impression and not body mass index.    
(2) Presenting clinical symptoms such as headaches, loss of vision, transient visual 
obscurations, double vision, nausea and vomiting and other symptoms.  
(3) presenting clinical signs such as visual acuity loss, abduction deficit, abnormal pupil 
reactions and papilloedema.  
(4) associations such as hypertension, diabetes mellitus, steroids (prednisone) and 
contraception.  
(5) treatment modalities such as weight loss, acetazolamide, optic nerve sheath 
fenestration, lumbar-peritoneal shunt and multiple lumbar punctures.  
(6) outcome measures of symptoms, abduction deficit, papilloedema, visual acuity and 
visual field.    
Papilloedema was classified as follows: (1) early (2) acute/established (3) chronic (4) 
vintage (5) atrophic.
33
  
The visual acuity was measured using a Snellen chart. The reason for using Snellen visual 
acuity as opposed to logMAR is that most of the journals referenced here used Snellen 
visual acuity and therefore it was easier to make comparisons. The visual acuity loss 
classification was based on the classifications used in a few studies including the 
Framingham, Baltimore, and Salisbury Eye studies and classified as follows:
34-37 
 
(1) Normal vision = ≥ 6/6 (i.e. 6/6 or better).  
(2) Adequate vision for driving = <6/6 ≥6/12.  
9 
(3) Mild visual acuity loss = <6/12 ≥6/18.  
(4) Moderate visual acuity loss = <6/18 ≥6/60.  
(5) Severe visual acuity loss = <6/60 ≥CF (counting fingers).  
(6) Profound visual acuity loss = <CF (worse than counting fingers).  
The visual acuity at the last/final visit was compared to that of the first visit and graded 
into improved, stable or worse. If the visual acuity between the first and last visit changed 
from one group to the other in the above visual acuity loss classification, than it was 
graded as improved or worse.  
The visual fields (central 30°) were generated by the Oculus automated perimeter. The 
visual field loss classification was based on the classifications used in Radhakrishnan’s and 
VanNewkirk’s studies.7, 37 It was classified as follows:  
(1) Normal = No visual field defect i.e. full field.  
(2) Mild loss = presence of at least 20
0 
radius field (≥ 20° radius field).  
(3) Moderate loss = <20
0 ≥100 radius field.  
(4) Severe loss = <10
0 ≥50 radius field.  
(5) Profound loss = <5
0 
radius field. 
 The visual field at the last visit was compared to that of the first visit and graded into 
improved, stable or worse. If the visual field between the first and last visit changed from 
one group to the other in the above visual field loss classification, than it was graded as 
improved or worse. In addition, the encroachment of the enlarged blind spot into the 
central 10̊ of the visual field equalled visual field loss and this was taken into consideration 
when grading the visual field into improved, stable or worse. 
Patients were regarded as legally blind if the VA was < 6/60 (worse than 6/60) and/or the 
VF was <10° radius field (worse than 10° radius field) i.e. severe to profound VA and/or 
VF loss.  
 
 The minimum follow up period between the first and last visit was 2 months. 
Statistics were performed using the statistical software SAS 9.1 (SAS Institute Inc., Cary, 
NC, USA). The graphs and pie charts were generated by this statistical programme. 
Calculations of the mean and range of the age of presentation, follow-up period and LPOP 
were performed by this programme. In addition, percentages were also calculated.   
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CHAPTER 3 
 
3.0 RESULTS 
 
3.1 DESCRIPTIVE ANALYSIS 
3.1.1 Demographic analysis 
There were 21 patients. All the patients were female and black.  
Age of presentation of patients ranged from 16 years to 50 years and the mean age was 
31.2 ± 8.9 years (Figure 3.1). 
The follow-up period (period between first and last/final visit) ranged from two to 77 
months and the mean follow-up period was 19.9 ± 20.1 months (Figure 3.2).                                               
Of the 21 patients, 71.4% were obese, 4.8% were not obese and in the remaining 23.8% 
obesity was not recorded [NR] (Figure 3.3).  
 
 
             Figure 3.1  Age distribution of patients presenting with IIH.  
11 
       
            
Figure 3.2  Distribution of follow-up period of IIH patients. 
 
 
              
   
Figure 3.3  Pie chart of analysis of obesity.  (NR = not recorded) 
12 
3.1.2 Clinical features 
 
The following results are summarized in Table 3.1 
All 21 IIH patients presented with symptoms.  
19 patients (90%) presented with headaches alone or in association with other symptoms. 
14 patients (67%) presented with visual loss alone or in association with other symptoms. 
13 patients (61.9%) presented with both headaches and visual loss.    
Eight out of the 21 patients (38%) had transient visual obscurations (TVO’s). All eight 
patients had concomitant headaches and six of the eight patients had concomitant visual 
loss i.e. none of these patients presented with TVO’s alone.  
Six patients (29%) had double vision.    
Four patients (19%) had associated nausea and vomiting, ten (48%) had no associated 
nausea and vomiting and in seven patients (33%), nausea and vomiting (NR) was not 
recorded. 
Two patients (9.5%) presented with other ocular symptoms in addition to headache; one 
patient presented with a right conjunctival ‘growth’ and the other presented with itchy 
eyes. 
The duration of symptoms before presentation ranged from two weeks to more than one 
year.  
 
 
Table 3.1  Presenting features 
          
Symptoms Number of patients n = 21 (%)                     
Headaches  19 (90%)      
Loss of vision  14 (67%)      
Transient visual 
obscurations 
   8 (38%)      
Double vision    6 (29%)      
Nausea and vomiting    4 (19%)      
Other                                                                          2 (9.5%)      
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3.1.3 Clinical signs on presentation 
 
The following results are summarized in Table 3.2 
Initial Snellen visual acuity of 19 of 42 eyes (45%) were normal (≥6/6). 16 eyes (38%) had 
adequate vision for driving (<6/6 ≥6/12) and seven eyes (17%)  had visual acuity loss [four 
(10%) had mild visual acuity loss (<6/12 ≥6/18), one (2%) had severe visual acuity loss 
(<6/60 ≥CF) and two (5%) had profound visual acuity loss (<CF)]. None of the patients 
had moderate visual acuity loss (<6/18 ≥6/60). 
Seven of the 21 patients (33%), on presentation, had abduction deficits i.e. abducens (sixth 
cranial nerve) paresis/palsies. Because two patients had unilateral abduction deficits, the 
number of eyes with abduction deficits was 12 (29%). 
Pupil reactions were abnormal in four of the 42 eyes (9.5%) i.e. four of the 21 patients 
(19%) had unilateral abnormal pupil reactions. Three patients had a relative afferent pupil 
defect (RAPD) and one had an afferent pupil defect (APD). 
 
All 21 IIH patients had papilloedema (bilateral swollen discs). The stage of papilloedema 
was documented in eight patients (38%): two had early papilloedema, three established 
papilloedema, one chronic papilloedema and two atrophic papilloedema. The stage of 
papilloedema was not documented in 13 patients. 
All 21 patients had normal neurological examinations.  
 
 
Table 3.2  Clinical presentations 
 Number of eyes  
   n = 42 (%) 
 
Visual acuity loss       7 (17%)     
Abduction deficit     12 (29%)     
Abnormal pupil reaction       4 (9.5%)     
Papilloedema       42 (100%)     
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3.1.4 Associations 
 
Medical Conditions 
Of the 21 patients, eight (38%) had systemic illnesses. The remaining 13 patients (62%) 
had no systemic illnesses. Seven out of the 21 patients (33%) had hypertension and the 
remaining one patient (5%) had diabetes.    
Pregnancy 
None of the 21 patients was pregnant. 
Medications / Drugs 
Six of the 21 patients (29%) were taking contraception. Two were taking oral 
contraception and four were taking injectables. 
Two of the 21 patients (9.5%) took oral prednisone prior to presentation; one patient was 
being treated for uveitis and the other was being treated for pulmonary disease.     
 
 
 
 
 
 
 
Table 3.3  Associations 
         
                           Number of patients   n=21 (%) 
Medical conditions   
Hypertension  7 (33%)  
Diabetes Mellitus                                                                          1 (5%) 
                                               
 
       
Medication/Drug history       
Prednisone                                                                                     2 (9.5%) 
      
Contraceptives               6 (29%)  
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3.1.5 Investigations 
 
All of the 21 IIH patients met the modified Dandy criteria with normal CT scans (no SOL 
and no ventriculomegaly) and normal CSF compositions. Four patients had additional MRI 
scans which showed no SOL and no ventriculomegaly. 
The mean lumbar puncture opening pressure (LPOP) in centimetres of water (cm H20) was 
34.67 ± 10.53 (range 20-55) [Figure 3.4]. 
. 
 
 
 
 
 
Figure 3.4  Box and Whisker plot of lumbar puncture opening pressure (LPOP). 
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3.1.6 Management 
 
All 21 IIH patients were treated after the initial visit i.e. after presentation.  
Weight loss was recorded in three of the 21 patients (14%). 
All 21 patients were treated with acetazolamide (Diamox). 
None of the 21 patients was treated with oral or intravenous steroids. 
Two of the 21 patients (9.5%) had optic nerve sheath fenestrations (ONSFs); one presented 
with severe unilateral visual impairment (<6/60 ≥CF) and the other with profound 
unilateral visual impairment (< CF) which did not improve following the procedure. The 
VA’s in the other eyes, on presentation, were 6/9 (adequate for driving) and 6/6 (normal) 
respectively. 
 Two of the 21 patients (9.5%) had lumbar-peritoneal shunts. One patient presented with 
6/9 vision (adequate for driving) and the other patient presented with 6/18 vision (mild 
visual impairment) in the worse eye.   
Of the 21 patients, six (28.6%) had multiple lumbar punctures (LPs). 
 
 
 
 
Table 3.4  Management  
       
                          Number of patients    n = 21  ( % )   
                              
         
Weight loss (recorded)   3 (14%)   
 
 
Acetazolamide 
(Diamox)                                     
                21 (100%) 
 
 
Optic nerve sheath fenestration (ONSF)                                             2 (9.5%) 
 
 
Lumbar-peritoneal shunt (LPS)                                                          2 (9.5%) 
 
 
Multiple lumbar punctures                                                                  6 (28.6%) 
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3.2 OUTCOME ANALYSIS 
 
3.2.1 Clinical Outcomes 
 
At the initial visit, all 21 IIH patients had symptoms and papilloedema. Seven patients 
(33%) had abduction deficits (abduction nerve paresis) i.e. 12 of the 42 eyes (29%) had 
abduction deficits.  
At the final visit, 19  patients (90%) had symptoms that  improved but 16 (76%) had 
persistent papilloedema. Two patients (9.5%) had unilateral abduction deficits i.e. two of 
the 42 eyes (5%) had abduction deficits. 
 
Table 3.5   Clinical outcomes      
        
   Initial  Final   
   Number of 
eyes 
 Number of 
eyes 
  
   n = 42 (%)  n = 42 (%)   
        
Abduction deficit  12 (29%)  2 (5%)   
Abnormal pupil 
reaction 
 4 (9.5%)  3 (7%)   
Papilloedema  42 (100%)  32 (76%)   
        
 
 
3.2.2 Visual Outcomes 
 
3.2.2.1 Visual acuity 
 
The initial and final Snellen visual acuities of each of the 21 patients are shown in 
Appendix (B). In addition, the analysis of the initial and final visual acuities is shown in 
Table 3.6 
The initial visual acuities of 19 of the 42 eyes (45%) were normal (≥6/6). 16 eyes (38%) 
had adequate vision for driving (<6/6 ≥6/12) and seven eyes (17%) had visual acuity loss. 
Four eyes (9.5%) had mild visual acuity loss (<6/12 ≥6/18), one eye (2.5%) had severe 
visual acuity loss (<6/60 ≥CF) and two eyes (5%) had profound visual acuity loss (<CF). 
None of the patients had moderate visual acuity loss (<6/18 ≥6/60). 
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The final visual acuities of 20 of the 42 eyes (48%) were normal. 17 eyes (40%) had 
adequate vision for driving (<6/6 ≥6/12) and five eyes (12%) had visual acuity loss. One 
eye (2.5%) had mild visual acuity loss (<6/12 ≥6/18), one eye (2.5%) had moderate visual 
acuity loss (<6/18 ≥6/60) and three eyes (7%) had profound visual acuity loss (<CF). None 
of the patients had severe visual acuity loss (<6/60 ≥CF). 
 From the initial to the final visit, visual acuities of 31 of the 42 eyes (74%) were stable; 
seven eyes (16%) improved and four eyes (10%) got worse (Table 3.7). The one patient 
that presented with severe visual acuity loss (<6/60 ≥CF) in one eye progressed to 
profound visual acuity loss (<CF). This patient, in addition to one of the patients that 
presented with unilateral profound visual acuity loss (<CF), had an optic nerve sheath 
fenestration (ONSF). None of the patients presented with bilateral severe (<6/60 ≥CF) or 
profound (<CF) visual acuity loss. 
 
 
 
Table 3.6 Analysis of initial and final visual acuities (based on data in Appendix  B). 
            
Visual Acuity (VA)   Initial VA                 Final VA 
     Number of eyes             Number of eyes 
      n=42(100%)       n=42(100%)  
Normal Vision  ≥ 6/6      19(45%)    20(48%)  
Adequate vision for driving <6/6  ≥6/12     16(38%)    17(40%)  
Mild visual acuity loss <6/12 ≥6/18        4(9.5%)      1(2.5%)  
Moderate visual acuity loss <6/18 ≥6/60     0(0%)      1(2.5%)  
Severe visual acuity loss <6/60 ≥counting fingers(CF)      1(2.5%)    0(0%)  
Profound visual acuity loss < counting fingers(CF)    2(5%)    3(7%)  
            
   Total number of eyes 42(100%)    42(100%)  
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Table 3.7  Analysis of visual acuity grading (based on data in Appendix B). 
   
Visual acuity Grading  Number of eyes 
    n=42(100%)     
       Improved     7(16%)     
 Stable   31(74%)     
 Worse     4(10%)     
         
                          Total number of eyes   42(100%)    
 
 
 3.2.2.2 Visual field 
 
The following results are summarized in Table 3.8 and Table 3.9. The analysis of visual 
field classification and blind spot size is shown in Table 3.8. The analysis of visual field 
grading is shown in Table 3.9  
Initial visual field loss occurred in 39 of the 42 eyes (93%). Initial visual field loss in nine 
of the 42 eyes (21%) was moderate (<20̊ ≥10̊ radius field), in 26 of 42 eyes (62%) was 
severe (<10̊ ≥5̊ radius field) and in four of 42 eyes (10%) was profound (<5̊ radius field). 
None of the patients had a normal visual field or mild visual field loss (≥20̊ radius field). 
26 of 42 eyes (62%) had enlarged blind spots, two (5%) had normal blind spots and blind 
spots of 11 eyes (26%) could not be determined because of severe or profound visual field 
loss. Visual field testing of three of the 42 eyes (7%) was not done because of severe or 
profound visual acuity loss  
Final visual field loss occurred in 36 eyes of the 42 eyes (86%). Final visual field loss in 
three of the 42 eyes (7%) was mild (≥20̊ radius field), in 25 of the 42 eyes (60%) was 
moderate (<20̊ ≥ 10̊), in seven of the 42 eyes (17%) was severe (<10̊ ≥5̊ radius field) and 
in one of 42 eyes (2%) was profound (<5̊ radius field). Three of the 42 eyes (7%) had 
normal visual fields. 21 of 42 eyes (50%) had enlarged blind spots, 13 (31%) had normal 
blind spots and blind spots of five eyes (12%) could not be determined because of severe 
or profound visual field loss. Visual field testing of three of the 42 eyes (7%) was not done 
because of severe or profound visual acuity loss. 
From the initial to the final visit, visual fields of 33 of the 42 eyes (79%) improved and six 
of the 42 eyes (14%) remained stable (Table 3.9). 
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None of the visual fields worsened. As mentioned above, visual field testing of three of the 
42 eyes (7%) was not done. 
26% of eyes had severe to profound visual impairment (i.e. visual acuity loss and/or visual 
field loss) at the final visit.   
 
 
Table 3.9  Analysis of visual field grading (based on data in Appendix C).   
Visual field grading  Number of eyes 
    n=42(100%)     
 Improved   33(79%)     
 Stable     6(14%)     
 Worse   0(0%)     
 VF not done  3(7%)     
         
             Total number of eyes 42(100%)    
 
 
Table 3.8  Analysis of visual field classification and blind spot size (based on data in    
                  Appendix C). 
Visual Field (VF) Classification:                                                     Initial VF (on 
presentation) 
Final VF 
(last visit) 
    Number of 
eyes  
Number of 
eyes 
         
No VF loss    0 (0%) 3 (7%) 
Mild VF loss             ≥20 ̊         radius field          0 (0%) 3 (7%) 
Moderate VF loss    <20  ̊≥10 ̊ radius field    9 (21%) 25 (60%) 
Severe VF loss          <10  ̊≥ 5 ̊  radius field  26 (62%)   7 (17%) 
Profound VF loss     <5 ̊           radius field    4 (10%) 1 (2%) 
VF not done    3 (7%) 3 (7%) 
         
                                       Total number of eyes                                                                                42 (100%)  42 (100%) 
         
         
Blind Spot:        
         
Enlarged     26 (62%) 21 (50%) 
Normal     2 (5%) 13 (31%) 
Unable to determine from VF  11 (26%)  5 (12%) 
VF not done    3 (7%) 3 (7%) 
         
                                       Total number of eyes         42 (100%)   42 (100%) 
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CHAPTER 4 
 
4.0 DISCUSSION 
 
Patient data of 21 of 32  IIH patients seen in the Neuro-ophthalmology clinic at St John 
Eye Hospital over a two year period (2006 and 2007) were available and this study is based 
on these 21 patients. All 21 patients were black African female. The preponderance of 
females and the high percentage of obesity (71.4%) reported in this study are shown in 
other studies.
1, 5-7, 9
 In one study, obesity occurred less frequently.
10
 The mean age at 
diagnosis, in this study, was 31.2 ± 8.9 years which was similar to other studies.
3, 9
 The 
range of follow-up (2-77 months) in this study was similar to another study.
7
 
The most common presenting symptom in IIH are usually headaches followed by transient 
visual obscurations (TVOs).
3, 5, 6, 10
 In this study, headache was the commonest symptom 
(90%) but sustained loss of vision was the second most common symptom (67%) with 
transient visual obscurations (TVOs) being the third most common symptom (38%). The 
possible reason for sustained loss of vision but not TVOs being the second most common 
symptom is that our patients may be presenting later. The other possible reason was the 
vision loss wrongfully recorded as sustained whereas it was transient.   
At presentation (initial visit), visual acuity loss was found in 17% of eyes. This figure was 
higher than that found in Wall and George’s study.5 Seven patients (33%) had abduction 
deficits (abduction nerve paresis/paralysis) at presentation. All patients that presented with 
diplopia had abduction deficits. The abnormal pupil reactions reported in 19% of patients 
in this study was similar to that reported in Wall and George’s study but lower than that 
reported in Corbett et al’s study.2, 5 In this study, three of the four patients that had 
unilateral abnormal pupil reactions (APD/RAPD) presented with unilateral severe to 
profound visual acuity loss. This was expected because these patients had atrophic 
papilloedema. 
In this study, 33% of the patients  had hypertension. This was higher than the 23% reported 
by Corbett et al.
 
and equal to the 33% reported by Ireland et al.
2, 4
 Two case-control studies 
reported a significant association between hypertension and IIH.
4, 6
 This association was 
not observed by Radhakrishnan et al.
7
 In Ireland et al’s study, ten of the 13 hypertensive 
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patients (77%) were ≤ 25 years.4  In this study, one of the seven hypertensive patients 
(14%) was ≤ 25 years of age; the other six patients were 35 years or older.    
Though IIH has been anecdotally associated with oral contraceptives, pregnancy and 
menstrual irregularities, Ireland et al., in their case-control study, reported no differences in 
case and control subjects regarding prior oral contraceptive-use, pregnancy histories and 
menstrual irregularities.
4
 In this study, two of the 21 patients were taking oral 
contraceptives at the time of diagnosis of IIH. Because one patient was taking prednisone 
and the other was obese, it was difficult to comment whether there was an association 
between oral contraceptive-use and IIH. None of the patients was pregnant at the time of 
diagnosis. Menstrual irregularities were not recorded.  
Though corticosteroid-use has been associated with IIH, Ireland et.al did not find a causal 
relationship between corticosteroid-use and IIH.
4
  In this study, two of the 21 IIH patients 
were taking prednisone prior to the diagnosis of IIH. It was difficult to determine whether 
there was an association between prednisone-use and IIH, because one patient was obese 
and the other was taking oral contraceptives.     
The mean lumbar puncture opening pressure (LPOP) in this study was 34.67 ± 10.53 cm 
H2O (range 20-55). Similar averages were found in other studies.
9, 10
 Kesler et al. 
suggested that the high lumbar puncture opening pressure may be due to obesity.
9
  
All 21 IIH patients were treated after the initial visit. Whether patients lost weight or not 
was recorded in only three of the 21 patients (14%). All patients were treated with 
acetazolamide (Diamox). Four of the 21 patients (19%) had surgery after failure of 
conservative management: two (9.5%) had optic nerve sheath fenestrations (ONSFs) for 
progressive visual loss and two (9.5%) had lumbar-peritoneal shunts for persistent 
headaches. Three of these four patients had multiple lumbar punctures while waiting for 
surgery. Although there is a lack of good randomized trials to guide management 
decisions, this sequence (i.e. from conservative to surgical treatment) in the management 
of IIH patients is widely accepted.
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In this study, all 21 patients had IIH symptoms and papilloedema at the initial visit (i.e. at 
presentation). At the initial visit seven patients (33%) had abduction deficits, seven eyes 
(17%) had visual acuity loss and 39 eyes (93%) had visual field loss. At the final visit, 19  
patients (90%) had symptoms that  improved but 16 (76%) had persistent papilloedema. 
Thus a significant number of patients had persistent papilloedema. However, a third of 
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patients with persistent papilloedema had a short follow–up period. If these patients were 
followed up for a longer period, the papilloedema in some of these patients may have 
resolved, resulting in a lower percentage of patients classified as having persistent 
papilloedema. Two patients (9.5%) had abduction deficits at the final visit. In Wall and 
George’s study 64% of patients had papilloedema and none had abduction deficits at the 
final visit.
5
  
13% of eyes at presentation and 10% of eyes at the final visit had visual acuity loss in Wall 
and George’s study.5 In this study, seven of the 42 eyes (17%) had visual acuity loss at 
presentation (initial visit) but at the final visit, five of the 42 eyes (12%) had visual acuity 
loss. There was no significant difference in visual acuity loss between the initial visit and 
the final visit. Comparing the visual acuity at the final visit to that of the initial visit, visual 
acuity in seven eyes (16%) improved, 31 (74%) remained stable and four (10%) worsened.  
In Wall and George’s study, 88% of eyes had visual field (automated) loss on presentation 
and at the final visit, 71% of eyes had visual field loss.
5
 In this study, 39 eyes (93%) had 
visual field (automated) loss at presentation (initial visit). At the final visit, 36 eyes (86%) 
had visual field loss. A much higher percentage of eyes had visual field loss than Snellen 
visual acuity loss indicating that visual fields are a much more sensitive measure of vision 
loss. Most of the eyes (62%) in the present study had severe (<10° ≥5° radius field) visual 
field loss at the initial visit. Most of the eyes (60%) had moderate (<20° ≥10° radius field) 
visual field loss at the final visit. Comparing the visual field loss at the final visit to that of 
the initial visit, visual fields in 33 eyes (79%) improved and in six eyes (14%) remained 
stable.   
Bruce et al. concluded that IIH in blacks is more aggressive and that blacks are 3.5 times 
more likely to develop severe visual loss than non-blacks.
11
 They reported severe visual 
loss in at least one eye in 23% of black patients and 7% of non-black patients at the final 
visit. In this study, 26% of patients had severe to profound visual impairment at the final 
visit i.e. 26% were legally blind at the final visit.  
Limitations of the study: (1) This was a retrospective study; (2) Small sample size; (3) 
Short follow-up period in some of the patients; (4) Obesity was determined according to 
personal impression and not body mass index (BMI); (5) Other associations of IIH such as 
menstrual irregularities were not included in the questionnaire; (6) weight loss as part of a 
management strategy was not recorded in most patients 
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CHAPTER 5 
 
5.0 CONCLUSION 
  
The findings in a cohort of 21 black African female IIH patients are similar to some other 
studies with regards to demographics, clinical features and clinical and visual outcomes.   
In this study, IIH occurred mainly in obese females in the reproductive age group.  
Although a third of the IIH patients in this study had hypertension, an association between 
IIH and hypertension could not be established. An association between IIH and prednisone 
or oral contraceptives was also not established in this study. 
Although 90% of patients reported improved symptoms following treatment, 76% of 
patients still had evidence of papilloedema at the final visit.   
The percentage of eyes with visual impairment assessed by Snellen visual acuity was lower 
than that assessed by visual field at presentation (initial visit) and at the final visit. 
Therefore visual field was found to be more sensitive than visual acuity in detecting visual 
impairment.  
Although 79% of eyes had visual fields which improved following treatment, 86% of eyes 
still had visual field loss at the final visit.  
Finally, in this study, a quarter of the patients, despite treatment, were legally blind clearly 
indicating that this condition is not benign.   
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APPENDIX A:  DATA CAPTURE SHEET  
 
Patient Number: 
Age:                                                        Sex                                            Race:   
HISTORY 
Symptoms:   Headaches                      
                        Visual loss 
                        Transient visual obscurations 
                        Double vision 
                        Nausea & vomiting 
                        Nil 
 
Duration of symptoms 
 
Associations:   Obesity or recent weight gain 
                           Medical conditions                                                List:                                                     
                           Pregnancy 
                           Medication or drug use                                        List: 
 
Examination: 
 
Visual acuity:    Initial           R                     L                             Last visit      R                    L              
Ocular motility:                      R                     L 
Pupil reactions:                      R                     L 
Fundus examination:       
               Optic discs                R                     L 
               Rest of fundus         R                     L  
Neurological examination:   
 
Investigations: 
 
Neuroimaging:               CT scan                                                 MRI 
Lumbar puncture:         Opening pressure                               CSF composition 
Visual field( Oculus ):    Initial     R                   L                        Last visit    R                    L  
                                           Grading:  Improved 
                                                             Stable         
                                                             Worse          
    
Management: 
 
Weight loss:                           
Medical:              Diamox                  Steroids    
Surgical:              ONSF                      Lumbar peritoneal shunt                  Multiple LP’S     
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APPENDIX B 
 
Visual acuity classification and grading of all IIH patients. 
 
Patient Number 
 
Right eye 
  
Left eye 
 
       VA Loss Classification Grading               VA Loss Classification Grading  
  Initial Final   Initial Final   
          
1  Normal Adequate Worse  Adequate Adequate    Stable  
2  Normal Normal    Stable  Normal Normal    Stable  
3  Adequate Normal    Improved Adequate Normal    Improved 
4  Normal Normal    Stable  Normal Normal    Stable  
5  Adequate Adequate    Stable  Profound Profound    Stable  
6  Normal Adequate Worse  Normal Normal    Stable  
7  Severe Profound    
Worse 
 Adequate Adequate    Stable  
8  Profound Profound    Stable  Normal Adequate    
Worse 
 
9  Normal Normal    Stable  Mild Adequate    Improved 
10  Normal Normal    Stable  Normal Normal    Stable  
11  Adequate Adequate    Stable  Adequate Adequate    Stable  
12  Normal Normal    Stable  Normal Normal    Stable  
13  Adequate Adequate    Stable  Adequate Adequate    Stable  
14  Normal Normal    Stable  Normal Normal    Stable  
15  Adequate Normal    Improved Adequate Normal    Improved 
16  Normal Normal    Stable  Adequate Adequate    Stable  
17  Mild Mild    Stable  Mild Adequate    Improved 
18  Adequate Adequate    Stable  Normal Normal    Stable  
19  Normal Normal    Stable  Mild Moderate    Improved 
20  Adequate Adequate    Stable  Adequate Adequate    Stable  
21  Normal Normal    Stable  Adequate Adequate    Stable  
          
          
 Number of right eyes 21              Number of left eyes 21  
     ↘  ↙   
   Total number of eyes 42    
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APPENDIX C 
Visual field classification and grading of all IIH patients. 
 
 
 Right eye                         Left eye  
Patient no.                  VF Loss Classification Grading                  VF Loss Classification Grading  
  Initial Final   Initial Final   
          
1  Moderate Moderate    Stable  Moderate Moderate Improved 
      ↑ Blind ↑Blind   
      spot- spot- not   
             involving involving   
                 central 10   ̊ central 10   ̊  
          
2  Moderate Moderate    Stable  Severe Moderate Improved 
3  Severe Moderate    Improved Severe Moderate Improved 
4  Severe Moderate    Improved Severe Moderate Improved 
5  Severe Severe    Stable             NP NP NP  
6  Moderate Moderate    Stable  Severe Moderate Improved 
7  NP NP    NP       Profound Severe Improved 
8  NP NP    NP       Profound Profound Stable  
9  Severe Severe    Stable  Severe Moderate Improved 
10  Moderate Mild    Improved       Moderate Mild Improved 
11  Profound Severe    Improved      Profound Severe Improved 
12  Severe Moderate    Improved Severe Moderate Improved 
13  Severe Moderate    Improved Severe Moderate Improved 
14  Severe Moderate    Improved Severe Moderate Improved 
15  Severe Moderate    Improved Severe Moderate Improved 
          
16  Severe Moderate    Improved Severe Severe Improved 
      ↑Blind ↑Blind   
      spot- spot- not   
                involving involving   
                   central 10   ̊ central 10   ̊  
          
17  Severe Moderate    Improved Severe Severe Improved 
      ↑ Blind ↑Blind   
      spot- spot- not   
                involving involving   
                   central 10   ̊ central 10   ̊  
          
18  Severe Moderate    Improved             Severe Moderate Improved 
19  Severe Moderate    Improved             Severe Moderate Improved 
20  Severe Mild    Improved             Moderate Normal Improved 
21  Moderate Normal    Improved             Moderate Normal Improved 
  NP=                                    
Not Possible 
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